APO Research
Talk to an analyst

APO RESEARCH · REPORT

Veterinary Lyme Disease Vaccines

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.

Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.

Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.

The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.

Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.

Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.

Selected research

Industry Growth & Trends

Global Veterinary Lyme Disease Vaccines Industry Growth and Trends Forecast to 2032

21 December 202591 pages

Choose your research edition.

Industry ResearchVeterinary Lyme Disease Vaccines Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Veterinary Lyme Disease Vaccines Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Veterinary Lyme Disease Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Veterinary Lyme Disease Vaccines Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Veterinary Lyme Disease Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Veterinary Lyme disease vaccines are companion-animal biologics designed to reduce the probability and magnitude of infection with Borreliella (Borrelia) burgdorferi sensu lato after exposure to competent Ixodes ticks. The commercial and clinical category is functionally canine; a limited feline line exists in parts of Europe, and there are no licensed equine or food-animal products. Use is risk-based rather than core and is paired with acaricides and environmental tick management. The etiologic agents are host-adapted spirochetes maintained in an enzootic cycle linking small mammals and certain birds with hard ticks. Larval and nymphal Ixodes acquire organisms during a blood meal, retain them transstadially, and transmit during subsequent feeding. Within unfed ticks, spirochetes occupy a vector-adapted state; attachment and feeding trigger a transcriptional switch toward mammalian-phase biology, down-regulating vector-phase genes and up-regulating mammalian-phase genes as organisms exit the midgut for the salivary glands. Geographically, veterinary and human hotspots mirror vector ranges: I. scapularis in the northeastern and upper midwestern United States with a coastal Pacific belt under I. pacificus; I. ricinus across temperate Europe; and I. persulcatus across northern Eurasia. North American canine disease is dominated by B. burgdorferi sensu stricto, whereas B. garinii and B. afzelii contribute materially in Europe and the UK; stable natural foci also occur across parts of northeastern Asia.

Two vaccine platforms encompass licensed products and map onto distinct biological bottlenecks. Bacterins are inactivated whole-cell preparations that present broad antigenic repertoires; in commerce they are typically bivalent by strain in North America and trivalent in Europe to align with regional sensu lato diversity. Recombinant protein subunits are defined-composition formulations built around outer-surface lipoproteins with established protective correlates. One branch uses lipidated outer surface protein A (OspA) as a single antigen; the other pairs OspA with an engineered OspC chimeric epitope protein (“chimeritope”) that concatenates linear epitopes from multiple OspC types to extend breadth. Mechanistically, anti-OspA antibodies act mainly within the feeding tick midgut, binding OspA on vector-phase organisms and impeding survival and transmission, whereas anti-OspC antibodies act in the early mammalian window at the bite site and draining tissues, promoting neutralization and opsonophagocytic clearance before hematogenous dissemination. The responses are temporally complementary and address distinct transmission bottlenecks.

Antigen-level detail underpins both design and diagnostics. OspA is a lipidated outer-membrane lipoprotein abundantly expressed by unfed tick-phase organisms; protective B-cell epitopes cluster toward the C-terminal domain, the locus of canonical neutralizing monoclonals, and OspA is down-regulated during feeding and host entry, which explains its principal value at the vector interface and its pairing with mammalian-phase antigens in some subunits. OspC is a smaller, dimeric lipoprotein whose transcription is strongly induced during tick feeding and the first days of mammalian infection; it contributes to early tissue invasion and complement interactions and is a dominant target of early humoral responses. OspC is highly polymorphic and partitioned into dozens of phylogenetic types maintained by recombination and frequency-dependent selection; antibody responses are largely type-specific and cross-protection is limited. Chimeritope designs address this constraint by assembling immunodominant linear segments—classically from the variable L5 and H5 regions—drawn from representative OspC types into a single recombinant antigen capable of broad binding across OspC diversity. In genomic context, OspA is encoded on lp54, OspC on cp26, and the vls cassette system on lp28-1 underpins antigenic variation during persistence; this plasmid architecture explains phase-specific expression and immune evasion. Serology follows from these rules: antibodies to the VlsE-derived C6 peptide track natural infection and are not induced by OspA-only vaccination, whereas bacterins and OspC-containing subunits broaden antibody profiles and require assay selection and clinical correlation to distinguish vaccine responses from infection.

Read the full market overview

Historically, the category progressed from whole-cell to defined-antigen formulations. Early licensed canine products in the 1990s were formalin-inactivated cell-lysate bacterins (e.g., LymeVax and Galaxy Lyme). The next phase introduced recombinant OspA subunits to avoid nonessential antigens and focus on vector-phase blockade. From the mid-2010s, OspA plus OspC chimeritope formulations appeared, targeting both the tick midgut and the early mammalian phase while addressing OspC’s strong polymorphism. This trajectory reflects a shift from breadth via whole-cell antigen overload to breadth-with-specificity via defined antigens, with corresponding gains in compositional clarity and mechanistic alignment to transmission biology.

The global burden aligns with vector ecology and surveillance intensity. In the United States, highest veterinary and human risk occurs from the mid-Atlantic through New England and the upper Midwest, with additional foci on the Pacific coast; in Canada, risk concentrates in southern Ontario, Québec, the Maritimes, and expanding prairie and coastal belts. In Europe, risk spans the UK and Ireland, the Benelux and Alpine corridors, Germany and Poland, the Baltics and Scandinavia, and northern Mediterranean foothills where I. ricinus is established. Across northern Eurasia, I. persulcatus supports foci from northeastern Europe through western Russia into Siberia and parts of the Far East. Outside North America and Europe many jurisdictions do not license canine Lyme vaccines and rely on acaricides and exposure management.

Current products in commerce resolve to a short, well-defined list whose differences are meaningful at the level of antigen strategy, breadth, and evidentiary posture rather than dose logistics. VANGUARD® crLyme is an OspA plus OspC chimeritope subunit; the OspC component presents a panel of linear epitopes drawn from diverse OspC types, aiming to maintain binding breadth across local OspC ecologies while pairing vector-phase interception with early mammalian-phase neutralization. This defined-composition approach yields strong titers to both components, challenge-model protection across infection and histopathology endpoints, and an extended duration-of-immunity label in its home market; trade-offs include broader serologic footprints that can complicate interpretation on certain assays and a dependence on epitope selection relative to regional OspC phylogeny. RECOMBITEK® Lyme (rLyme) is a non-adjuvanted, lipidated OspA subunit that emphasizes a tight antigen profile and a vector-interface mechanism; benefits include minimal extraneous proteins and preserved interpretability of C6-based diagnostics, while constraints center on the absence of an explicit OspC component, making timely transmission interception and booster maintenance central to performance. Nobivac® Lyme is a bivalent bacterin built around two B. burgdorferi sensu stricto strains selected to emphasize OspA and OspC expression characteristics; it delivers broad borreliacidal responses with long field experience and a 12-month duration label in its home market, balanced against the inherent complexity of whole-cell formulations and limited public standardization of OspC expression in production cultures. Duramune® Lyme and Ultra Duramune® Lyme—and their successor branding TruCan™ Lyme and TruCan™ Ultra Lyme—are bivalent bacterins positioned for breadth and for integration into combination presentations with Leptospira or broader canine cores; strengths include robust whole-cell immunogenic breadth and portfolio flexibility, while constraints mirror the bacterin class: extraneous-antigen overhead, culture-stage expression variability, and the fact that reduced fill volume by itself does not evidence superior protection. In Europe and the UK, Borrelym 3 and Merilym 3 are trivalent bacterins that include B. afzelii, B. garinii, and B. burgdorferi sensu stricto to match regional sensu lato diversity; they are well aligned to I. ricinus regions but, as whole-cell products, share the class’s compositional constraints and have limited public species-specific protection data versus each included sensu lato species. Within the same manufacturer’s portfolio, Biocan B is a canine bacterin used where national registrations permit, and Biofel B is a niche feline bacterin available in limited jurisdictions; both follow the bacterin paradigm with corresponding advantages in breadth and constraints in specificity and transparency.

Taken together, veterinary Lyme disease vaccines are best understood as a small, mechanism-anchored category defined by two platforms, two principal antigens with distinct temporal loci of action, and a finite set of market models whose antigen strategies map directly onto transmission biology. Bacterins trade compositional complexity for breadth; OspA subunits trade breadth for precision at the vector interface; OspA plus OspC chimeritopes aim to recapture breadth with defined antigens by spanning vector and early mammalian phases. Regional epidemiology and OspC phylogeny shape optimal fit, diagnostics must be interpreted with platform awareness, and program value is maximized when vaccination is integrated with acaricides and exposure management in dogs genuinely at risk.

The global Veterinary Lyme Disease Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Veterinary Lyme Disease Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Veterinary Lyme Disease Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for Veterinary Lyme Disease Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Veterinary Lyme Disease Vaccines include Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health and Bioveta, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Veterinary Lyme Disease Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Veterinary Lyme Disease Vaccines market size, estimates, and forecasts are presented in terms of sales volume (k doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Veterinary Lyme Disease Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Veterinary Lyme Disease Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Veterinary Lyme Disease Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Veterinary Lyme Disease Vaccines Market by Company

Zoetis

Boehringer Ingelheim

Elanco

Merck Animal Health

Bioveta

Veterinary Lyme Disease Vaccines Segment by Type

Recombinant Subunit Vaccines

Bacterin Vaccines

Veterinary Lyme Disease Vaccines Segment by Application

Canine

Feline

Veterinary Lyme Disease Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Lyme Disease Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Veterinary Lyme Disease Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Lyme Disease Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Veterinary Lyme Disease Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Veterinary Lyme Disease Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Recombinant Subunit Vaccines Table 2. Major Company of Bacterin Vaccines Table 3. Global Veterinary Lyme Disease Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 5. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type (2021-2026) Table 6. Global Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 7. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type (2021-2026) Table 8. Global Veterinary Lyme Disease Vaccines Price by Type (2021-2026) & (USD/dose) Table 9. Global Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (k doses) Table 10. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type (2027-2032) Table 11. Global Veterinary Lyme Disease Vaccines Sales by Type (2027-2032) & (US$ Million) Table 12. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type (2027-2032) Table 13. Global Veterinary Lyme Disease Vaccines Price by Type (2027-2032) & (USD/dose) Table 14. North America Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 15. North America Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 17. Europe Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 19. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 21. Latin America Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (k doses) Table 23. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Type (2021-2026) & (US$ Million) Table 24. Veterinary Lyme Disease Vaccines Industry Trends Table 25. Veterinary Lyme Disease Vaccines Industry Drivers Table 26. Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges Table 27. Veterinary Lyme Disease Vaccines Industry Restraints Table 28. Global Veterinary Lyme Disease Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Veterinary Lyme Disease Vaccines Revenue Market Share by Company (2021-2026) Table 30. Global Veterinary Lyme Disease Vaccines Sales by Company (2021-2026) & (k doses) Table 31. Global Veterinary Lyme Disease Vaccines Sales Share by Company (2021-2026) Table 32. Global Veterinary Lyme Disease Vaccines Market Price by Company (2021-2026) & (USD/dose) Table 33. Global Veterinary Lyme Disease Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Veterinary Lyme Disease Vaccines Major Company Production Sites and Headquarters Table 35. Global Veterinary Lyme Disease Vaccines Company, Product Type & Application Table 36. Global Veterinary Lyme Disease Vaccines Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Veterinary Lyme Disease Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Veterinary Lyme Disease Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Veterinary Lyme Disease Vaccines Sales by Region (2021-2026) & (k doses) Table 41. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Region (2021-2026) Table 42. Global Veterinary Lyme Disease Vaccines Sales by Region (2021-2026) & (US$ Million) Table 43. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Region (2021-2026) Table 44. Global Veterinary Lyme Disease Vaccines Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 45. Global Veterinary Lyme Disease Vaccines Sales by Region (2027-2032) & (k doses) Table 46. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Region (2027-2032) Table 47. Global Veterinary Lyme Disease Vaccines Sales by Region (2027-2032) & (US$ Million) Table 48. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Region (2027-2032) Table 49. Global Veterinary Lyme Disease Vaccines Sales (k doses), Value (US$ Million), Price (USD/dose) and Gross Margin (2027-2032) Table 50. Global Veterinary Lyme Disease Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 52. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application (2021-2026) Table 53. Global Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 54. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application (2021-2026) Table 55. Global Veterinary Lyme Disease Vaccines Price by Application (2021-2026) & (USD/dose) Table 56. Global Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (k doses) Table 57. Global Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application (2027-2032) Table 58. Global Veterinary Lyme Disease Vaccines Sales by Application (2027-2032) & (US$ Million) Table 59. Global Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application (2027-2032) Table 60. Global Veterinary Lyme Disease Vaccines Price by Application (2027-2032) & (USD/dose) Table 61. North America Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 62. North America Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 64. Europe Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 66. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 68. Latin America Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (k doses) Table 70. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Application (2021-2026) & (US$ Million) Table 71. Zoetis Company Information Table 72. Zoetis Business Overview Table 73. Zoetis Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 74. Zoetis Veterinary Lyme Disease Vaccines Product Portfolio Table 75. Zoetis Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Elanco Company Information Table 82. Elanco Business Overview Table 83. Elanco Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 84. Elanco Veterinary Lyme Disease Vaccines Product Portfolio Table 85. Elanco Recent Development Table 86. Merck Animal Health Company Information Table 87. Merck Animal Health Business Overview Table 88. Merck Animal Health Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 89. Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio Table 90. Merck Animal Health Recent Development Table 91. Bioveta Company Information Table 92. Bioveta Business Overview Table 93. Bioveta Veterinary Lyme Disease Vaccines Sales (k doses), Revenue (US$ Million), Price (USD/dose) and Gross Margin (2021-2026) Table 94. Bioveta Veterinary Lyme Disease Vaccines Product Portfolio Table 95. Bioveta Recent Development Table 96. North America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 97. North America Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 98. North America Veterinary Lyme Disease Vaccines Sales Market Share by Country (2021-2026) Table 99. North America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032) & (k doses) Table 100. North America Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2027-2032) Table 101. North America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. North America Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 103. North America Veterinary Lyme Disease Vaccines Market Share by Country (2021-2026) Table 104. North America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. North America Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2027-2032) Table 106. Europe Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 107. Europe Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 108. Europe Veterinary Lyme Disease Vaccines Sales Market Share by Country (2021-2026) Table 109. Europe Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032) & (k doses) Table 110. Europe Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2027-2032) Table 111. Europe Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Europe Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 113. Europe Veterinary Lyme Disease Vaccines Market Share by Country (2021-2026) Table 114. Europe Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Europe Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 118. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share by Country (2021-2026) Table 119. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032) & (k doses) Table 120. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 123. Asia-Pacific Veterinary Lyme Disease Vaccines Market Share by Country (2021-2026) Table 124. Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Asia-Pacific Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2027-2032) Table 126. Latin America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 127. Latin America Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 128. Latin America Veterinary Lyme Disease Vaccines Sales Market Share by Country (2021-2026) Table 129. Latin America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032) & (k doses) Table 130. Latin America Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2027-2032) Table 131. Latin America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Latin America Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 133. Latin America Veterinary Lyme Disease Vaccines Market Share by Country (2021-2026) Table 134. Latin America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Latin America Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (k doses): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country (2021-2026) & (k doses) Table 138. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share by Country (2021-2026) Table 139. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032) & (k doses) Table 140. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 143. Middle East and Africa Veterinary Lyme Disease Vaccines Market Share by Country (2021-2026) Table 144. Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Middle East and Africa Veterinary Lyme Disease Vaccines Market Share Forecast by Country (2027-2032) Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Veterinary Lyme Disease Vaccines Distributors List Table 149. Veterinary Lyme Disease Vaccines Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Veterinary Lyme Disease Vaccines Image Figure 2. Global Veterinary Lyme Disease Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Veterinary Lyme Disease Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Veterinary Lyme Disease Vaccines Sales (2021-2032) & (k doses) Figure 5. Recombinant Subunit Vaccines Image Figure 6. Global Recombinant Subunit Vaccines Sales YoY Growth (2021-2032) & (k doses) Figure 7. Bacterin Vaccines Image Figure 8. Global Bacterin Vaccines Sales YoY Growth (2021-2032) & (k doses) Figure 9. Global Veterinary Lyme Disease Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Veterinary Lyme Disease Vaccines Market Share by Type 2025 VS 2032 Figure 11. North America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2025 Figure 12. North America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2025 Figure 13. Europe Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. Europe Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Veterinary Lyme Disease Vaccines Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Canine Image Figure 24. Global Canine Sales YoY Growth (2021-2032) & (k doses) Figure 25. Feline Image Figure 26. Global Feline Sales YoY Growth (2021-2032) & (k doses) Figure 27. Global Veterinary Lyme Disease Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Veterinary Lyme Disease Vaccines Market Share by Application 2025 VS 2032 Figure 29. North America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2025 Figure 30. North America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2025 Figure 31. Europe Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2025 Figure 32. Europe Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Market Share in Value by Application in 2025 Figure 39. North America Veterinary Lyme Disease Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 40. North America Veterinary Lyme Disease Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Veterinary Lyme Disease Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Veterinary Lyme Disease Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 44. Europe Veterinary Lyme Disease Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Veterinary Lyme Disease Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 48. Asia-Pacific Veterinary Lyme Disease Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Veterinary Lyme Disease Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Veterinary Lyme Disease Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 52. Latin America Veterinary Lyme Disease Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Veterinary Lyme Disease Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k doses) Figure 56. Middle East and Africa Veterinary Lyme Disease Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Veterinary Lyme Disease Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Veterinary Lyme Disease Vaccines Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Veterinary Lyme Disease Vaccines Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Subunit Vaccines
  • Bacterin Vaccines
Applications
  • Canine
  • Feline
Companies covered
  • Zoetis
  • Boehringer Ingelheim
  • Elanco
  • Merck Animal Health
  • Bioveta

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Veterinary Lyme Disease Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Veterinary Lyme Disease Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Veterinary Lyme Disease Vaccines Market by Type
  6. 1.3.1 Recombinant Subunit Vaccines
  7. 1.3.2 Bacterin Vaccines
  8. 1.4 Global Veterinary Lyme Disease Vaccines Market Size by Type
  9. 1.4.1 Global Veterinary Lyme Disease Vaccines Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Veterinary Lyme Disease Vaccines Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Veterinary Lyme Disease Vaccines Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Veterinary Lyme Disease Vaccines Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Veterinary Lyme Disease Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Veterinary Lyme Disease Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Veterinary Lyme Disease Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Veterinary Lyme Disease Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Veterinary Lyme Disease Vaccines Industry Trends
  2. 2.2 Veterinary Lyme Disease Vaccines Industry Drivers
  3. 2.3 Veterinary Lyme Disease Vaccines Industry Opportunities and Challenges
  4. 2.4 Veterinary Lyme Disease Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Veterinary Lyme Disease Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Veterinary Lyme Disease Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Veterinary Lyme Disease Vaccines Price (2021-2026)
  4. 3.4 Global Veterinary Lyme Disease Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Veterinary Lyme Disease Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Veterinary Lyme Disease Vaccines Company, Product Type & Application
  7. 3.7 Global Veterinary Lyme Disease Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Veterinary Lyme Disease Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Veterinary Lyme Disease Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Veterinary Lyme Disease Vaccines Tier 1, Tier 2, and Tier 3
4 Veterinary Lyme Disease Vaccines Regional Status and Outlook
  1. 4.1 Global Veterinary Lyme Disease Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Veterinary Lyme Disease Vaccines Historic Market Size by Region
  3. 4.2.1 Global Veterinary Lyme Disease Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Veterinary Lyme Disease Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Veterinary Lyme Disease Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Veterinary Lyme Disease Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Veterinary Lyme Disease Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Veterinary Lyme Disease Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Veterinary Lyme Disease Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Veterinary Lyme Disease Vaccines by Application
  1. 5.1 Veterinary Lyme Disease Vaccines Market by Application
  2. 5.1.1 Canine
  3. 5.1.2 Feline
  4. 5.2 Global Veterinary Lyme Disease Vaccines Market Size by Application
  5. 5.2.1 Global Veterinary Lyme Disease Vaccines Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Veterinary Lyme Disease Vaccines Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Veterinary Lyme Disease Vaccines Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Veterinary Lyme Disease Vaccines Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Veterinary Lyme Disease Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Veterinary Lyme Disease Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Veterinary Lyme Disease Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Veterinary Lyme Disease Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zoetis
  2. 6.1.1 Zoetis Company Information
  3. 6.1.2 Zoetis Business Overview
  4. 6.1.3 Zoetis Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zoetis Veterinary Lyme Disease Vaccines Product Portfolio
  6. 6.1.5 Zoetis Recent Developments
  7. 6.2 Boehringer Ingelheim
  8. 6.2.1 Boehringer Ingelheim Company Information
  9. 6.2.2 Boehringer Ingelheim Business Overview
  10. 6.2.3 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim Veterinary Lyme Disease Vaccines Product Portfolio
  12. 6.2.5 Boehringer Ingelheim Recent Developments
  13. 6.3 Elanco
  14. 6.3.1 Elanco Company Information
  15. 6.3.2 Elanco Business Overview
  16. 6.3.3 Elanco Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Elanco Veterinary Lyme Disease Vaccines Product Portfolio
  18. 6.3.5 Elanco Recent Developments
  19. 6.4 Merck Animal Health
  20. 6.4.1 Merck Animal Health Company Information
  21. 6.4.2 Merck Animal Health Business Overview
  22. 6.4.3 Merck Animal Health Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Animal Health Veterinary Lyme Disease Vaccines Product Portfolio
  24. 6.4.5 Merck Animal Health Recent Developments
  25. 6.5 Bioveta
  26. 6.5.1 Bioveta Company Information
  27. 6.5.2 Bioveta Business Overview
  28. 6.5.3 Bioveta Veterinary Lyme Disease Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bioveta Veterinary Lyme Disease Vaccines Product Portfolio
  30. 6.5.5 Bioveta Recent Developments
7 North America by Country
  1. 7.1 North America Veterinary Lyme Disease Vaccines Sales by Country
  2. 7.1.1 North America Veterinary Lyme Disease Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Veterinary Lyme Disease Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Veterinary Lyme Disease Vaccines Market Size by Country
  6. 7.2.1 North America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Veterinary Lyme Disease Vaccines Sales by Country
  2. 8.1.1 Europe Veterinary Lyme Disease Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Veterinary Lyme Disease Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Veterinary Lyme Disease Vaccines Market Size by Country
  6. 8.2.1 Europe Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Veterinary Lyme Disease Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Veterinary Lyme Disease Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Veterinary Lyme Disease Vaccines Sales by Country
  2. 10.1.1 South America Veterinary Lyme Disease Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Veterinary Lyme Disease Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Veterinary Lyme Disease Vaccines Market Size by Country
  6. 10.2.1 South America Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Veterinary Lyme Disease Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Veterinary Lyme Disease Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Veterinary Lyme Disease Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Veterinary Lyme Disease Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Veterinary Lyme Disease Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Veterinary Lyme Disease Vaccines Value Chain Analysis
  2. 12.1.1 Veterinary Lyme Disease Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Veterinary Lyme Disease Vaccines Production Mode & Process
  7. 12.2 Veterinary Lyme Disease Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Veterinary Lyme Disease Vaccines Distributors
  10. 12.2.3 Veterinary Lyme Disease Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst